RT Book, Section
A1 Grimes, Pearl E.
A2 Kelly, A. Paul
A2 Taylor, Susan C.
A2 Lim, Henry W.
A2 Serrano, Ana Maria Anido
SR Print(0)
ID 1161547292
T1 Vitiligo
T2 Taylor and Kelly's Dermatology for Skin of Color, 2e
YR 2016
FD 2016
PB McGraw-Hill Education
PP New York, NY
SN 9780071805520
LK dermatology.mhmedical.com/content.aspx?aid=1161547292
RD 2024/04/24
AB KEY  POINTSVitiligo  has  an  equal  incidence  in  all  types  of  skin  color.Given  the  contrast  between  the  depigmented  patches  and  an  individual’s  normal  skin  tones,  this  disease  is  most  disfiguring  for  those  with  darker  skin  of  color.Between  20%  and  30%  of  patients  report  the  disease  in  first-  and  second-degree  relatives.In  vitiligo,  an  absence  of  melanocytes  is  the  predominant  histologic  change.The  popular  pathogenetic  mechanisms  for  vitiligo  include  autoimmune,  genetic,  neural,  biochemical,  and  autocytotoxic  causes.Vitiligo  patients  have  an  increased  frequency  of  other  autoimmune  disorders,  including  Hashimoto  thyroiditis,  Graves  disease,  pernicious  anemia,  and  Addison  disease.Baseline  laboratory  tests  should  include  a  comprehensive  metabolic  panel,  and  thyroid  function,  antinuclear  antibody,  and  thyroid  peroxidase  antibody  tests.The  therapeutic  objectives  should  include  both  the  stabilization  and  repigmentation  of  the  vitiliginous  lesions.The  therapies  for  limited  areas  of  involvement  include  topical  steroids,  topical  immunomodulators,  calcipotriol,  and  targeted  phototherapy.For  patients  with  vitiligo  affecting  more  than  15%  to  20%  of  their  body’s  surface  area,  optimal  results  can  be  achieved  with  narrow-band  ultraviolet  B  phototherapy.